Breast Cancer Care in Bavaria for patients with Metastatic Disease

Recruiting

• Conditions: TNM pTx pNx M1 oder pN1-3.; C50; C76; C77; C78; C79; C80; Malignant neoplasm of breast; Malignant neoplasm of other and ill-defined sites; Secondary and unspecified malignant neoplasm of lymph nodes

• Registration Number: DRKS00026601
• Lead Sponsor: niversitätsklinikum Würzburg, Frauenklinik und Poliklinik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 227

Inclusion Criteria

Consecutively treated patients with the inclusion criteria:
- Advanced or metastatic breast cancer (ICD10 code: C50; C76-C80); Tumor formula: pTx pNx M1 or pN1-3 regardless of T stage and metastasis
- Written declaration of consent (e.g. for comparison of cancer registries)
- Residence in Bavaria

Exclusion Criteria

- <18 years
- No advanced or metastatic breast cancer (ICD10 code: C50; C76-C80) (patients without the desired tumor formula: pTx pNx M1 or pN1-3 regardless of T stage and metastasis)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Estimation of the prevalence of guideline-compliant therapy of advanced / metastatic breast cancer with an eCRF (doctor's questionnaire) when the patient is included.<br>Which consists of the Charlson Comorbidity Index as a standardized measuring instrument, and other questions (in-house developments).

Secondary Outcome Measures

Name	Time	Method
Factors influencing the frequency of guideline-compliant therapy of advanced / metastatic breast cancer, influence of guideline-compliant / non-guideline-compliant therapy of advanced / metastatic breast cancer on patient-relevant outcomes, quality of life, needs of patients and relatives, adherence to drug therapy, evaluation of BRE-BY -MED app